Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 38-47 , February 2004

Gastrointestinal mucositis

References 

  1. Keefe DM, Goland GJ, Brealey J, et al.  Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 2000;47:632–637
  2. Keefe DMK. The effect of cytotoxic chemotherapy on the mucosa of the small intestine. Adelaide: University of Adelaide, Department of Medicine; 1998;
  3. Pico J-L, Avila-Garavito A, Naccache P. Mucositis (its occurrence, consequences, and treatment in the oncology setting). Oncologist. 1998;3:446–451
  4. Sonis ST, Haley JD. Biologicals and immunologicals (pharmacological attenuation of chemotherapy-induced oral mucositis). Exp Opin Invest Drugs. 1996;5:1155–1162
  5. Keefe DM, Cummins AG, Kotasek D, et al.  Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci. 1997;92:385–389
  6. Trier JS. Morphological alterations induced by methotrexate in the mucosa of human proximal intestine I. Serial observations by light microscopy. Gastroenterology. 1962;42:295–305
  7. Trier JS. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine II. Electron microscopic observations. Gastroenterology. 1962;43:407–424
  8. Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389
  9. Walsh D. Deep traumatism from roentgen ray exposure. BMJ. 1897;July:273–374
  10. Gibson RJ, Bowen JM, Inglis MRB, et al.  Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol. 2003;18:1095–1100
  11. Gibson RJ, Keefe DM, Clarke JM, et al.  The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol. 2002;50:53–58
  12. Gibson RJ, Keefe DM, Thompson FM, et al.  Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci. 2002;47:2751–2757
  13. Sonis ST, Tracey C, Shklar G, et al.  An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1990;69:437–443
  14. Sonis ST, Tracey C, Shklar G, et al.  Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 1992;74:749–755
  15. Sonis ST, Lindquist L, Van Vugt A, et al.  Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res. 1994;54:1135–1138
  16. Sonis ST. Mucositis as a biological process (a new hypothesis for the development of chemotherapy-induced stomatotoxicity). Oral Oncol. 1998;34:39–43
  17. Fajardo LF, Berthrong M, Anderson RE. Alimentary tract. In:  Fajardo LF,  Berthrong M,  Anderson RE editor. Radiation Pathology. 2001;p. 209–247 New York
  18. Carr KE. Effects of radiation damage on intestinal morphology. Int Rev Cytol. 2001;208:1–119
  19. Hauer-Jensen M, Wang J, Denham JW. Mechanisms and modification of the radiation response of gastrointestinal organs. In:  Milas L,  Ang KK,  Nieder C editor. Biological Modification of Radiation Response. 2002; Heidelberg: (in press)
  20. Yavuz MN, Yavuz AA, Aydin F, et al.  The efficacy of octreotide in the therapy of acute radiation-induced diarrhea (a randomized controlled study). Int J Radiat Oncol Biol Phys. 2002;54:195–202
  21. Hauer-Jensen M, Wang J, Denham JW. Bowel injury-current and evolving management strategies. Semin Radiat Oncol. 2003;13:189–202
  22. Dietz DW, Remzi FH, Fazio VW. Strictureplasty for obstructing small-bowel lesions in diffuse radiation enteritis-successful outcome in five patients. Dis Colon Rectum. 2001;44:1772–1777
  23. Kochhar R, Patel F, Dhar A, et al.  Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci. 1991;36:103–107
  24. O’Brien PC, Franklin CI, Dear KBG, et al.  A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol. 1997;45:117–123
  25. Martenson JA, Bollinger JW, Sloan JA, et al.  Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy (a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial). J Clin Oncol. 2000;18:1239–1245
  26. Kneebone A, Mameghan H, Bolin T, et al.  The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy (a double-blind, randomized trial). Int J Radiat Oncol Biol Phys. 2001;51:628–635
  27. Stellamans K, Lievens Y, Lambin P, et al.  Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. Radiother Oncol. 2003;65:105–108
  28. Rubinstein E, Ibsen T, Rasmussen RB, et al.  Formalin treatment of radiation-induced hemorrhagic proctitis. Am J Gastroenterol. 1986;81:44–45
  29. Saclarides TJ, King DJ, Franklin JL, et al.  Formalin instillation for refractory radiation-induced hemorrhagic proctitis. Dis Colon Rectum. 1996;39:196–199
  30. Counter SF, Froese DP, Hart MJ. Prospective evaluation of formalin therapy for radiation proctitis. Am J Surg. 1999;177:396–398
  31. Jensen DM, Machicado GA, Cheng S, et al.  A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc. 1997;45:20–25
  32. Leuchter RS, Petrilli ES, Dwyer RM, et al.  YAG laser therapy of rectosigmoid bleeding due to radiation injury. Obstet Gynecol. 1982;59:65–67
  33. Taylor JG, Disario JA, Buchi KN. Argon laser therapy for hemorrhagic radiation proctopathy (long term results). Gastrointest Endosc. 1993;39:641–644
  34. Carbatzas C, Spencer GM, Thorpe SM, et al.  Yag laser treatment for bleeding from radiation proctitis. Endoscopy. 1996;28:497–500
  35. Taylor JG, Disario JA, Bjorkman DJ. KTP laser therapy for bleeding from chronic radiation proctopathy. Gastrointest Endosc. 2000;52:353–357
  36. Fantin AC, Binek J, Suter WR, et al.  Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc. 1999;49:515–518
  37. Tam W, Moore J, Schoeman M. Treatment of radiation proctitis with argon plasma coagulation. Endoscopy. 2000;32:667–672
  38. Smith S, Wallner K, Dominitz JA, et al.  Argon beam coagulation for rectal bleeding after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:636–646
  39. Kaassis M, Oberti E, Burtin P, et al.  Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis. Endoscopy. 2002;32:673–676
  40. Zimmermann FB, Feldmann HJ. Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Strahlenther Onkol. 1998;174:85–89
  41. Feldmeier JJ, Heimbach RD, Davolt DA, et al.  Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Undersea Hyperb Med. 1996;24:215–216
  42. Moon RE, Feldmeier JJ. Hyperbaric oxygen (an evidence based approach to its application). Undersea Hyperb Med. 2002;29:1–3
  43. Kouvaris J, Kouloulias V, Malas E, et al.  Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 2003;179:167–174
  44. Athanassious H, Antonadou D, Coliarakis N, et al.  Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas (results of a randomized trial). Int J Radiat Oncol Biol Phys. 2003;56:1154–1160
  45. Antonadou D, Coliarakis N, Synodinou M. Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–922
  46. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification (preliminary findings). Semin Radiat Oncol. 2002;29:38–41
  47. Leong SS, Tan EH, Fong KW, et al.  Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003;21:1767–1774
  48. Ben-Joseph E, Han S, Tobi M, et al.  Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol. 2002;12:81–85
  49. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector?. Radiother Oncol. 2000;57:113–118
  50. Stickle RL, Epperly MW, Klein E, et al.  Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. Radiat Oncol Invest. 1999;7:204–217
  51. Guo H, Wolfe D, Epperly MW, et al.  Gene transfer of human manganese superoxide dismutase protects small intestinal villi from radiation injury. J Gastrointest Surg. 2003;7:229–236
  52. Hanson WR, Thomas C. 16,16-Dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat Res. 1983;96:393–398
  53. Tomas-de la Vega JE, Banner BF, Hubbard M, et al.  Cytoprotective effect of prostaglandin E2 in irradiated rat ileum. Surg Gynecol Obstet. 1984;158:39–45
  54. Keelan M, Walker K, Cheeseman CI, et al.  Two weeks of oral synthetic E2 prostaglandin (enprostil) improves the intestinal morphological but not the absorptive response in the rat to abdominal irradiation. Digestion. 1992;53:101–107
  55. Delaney JP, Bonsack ME, Felemovicius I. Misoprostol in the intestinal lumen protects against radiation injury of the mucosa of the small bowel. Radiat Res. 1994;137:405–409
  56. Khan AM, Birk JW, Anderson JC, et al.  A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis syndrome in prostate cancer patients. Am J Gastroenterol. 2000;95:1961–1966
  57. Farrell CL, Bready JV, Rex KL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933–939
  58. Khan WB, Shui C, Ning S, et al.  Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res. 1997;148:248–253
  59. Zheng H, Wang J, Koteliansky VE, et al.  Recombinant soluble transforming growth factor-b type II receptor ameliorates radiation enteropathy in the mouse. Gastroenterology. 2000;119:1286–1296
  60. Brown MS, Buchanan RB, Karran SJ. Clinical observations on the effects of elemental diet supplementation during irradiation. Clin Radiol. 1980;31:19–20
  61. Craighead PS, Young S. Phase II study assessing the feasibility of using elemental supplements to reduce acute enteritis in patients receiving radical pelvic radiotherapy. Am J Clin Oncol. 1998;21:573–578
  62. Douglass HO, Milliron S, Nava H, et al.  Elemental diet as an adjuvant for patients with locally advanced gastrointestinal cancer receiving radiation therapy (a prospectively randomized study). Jpn J Parenter Enteral Nutr. 1978;2:682–686
  63. Foster KJ, Brown MS, Alberti KG. The metabolic effects of abdominal irradiation in man with and without dietary therapy with and elemental diet. Clin Radiol. 1980;31:13–17
  64. McArdle AH, Reid EC, Laplante MP, et al.  Prophylaxis against radiation injury. The use of elemental diet prior to and during radiotherapy for invasive bladder cancer and in early postoperative feeding following radical cystectomy and ileal conduit. Arch Surg. 1986;121:879–885
  65. Klimberg VS, Souba WW, Olson DJ. Prophylactic glutamine protects intestinal mucosa from radiation injury. Cancer. 1990;66:62–68
  66. Campos FG, Waitzberg DL, Mucerino DR. Protective effects of glutamine enriched diets on acute actinic enteritis. Nutricion Hospitalaria. 1996;11:167–177
  67. McArdle AH. Elemental diets in treatment of gastrointestinal injury. Adv Biosci. 1994;94:201–206
  68. Hwang JM, Chan DC, Chang TM, et al.  Effects of oral arginine and glutamine on radiation-induced injury in the rat. J Surg Res. 2003;109:149–154
  69. Kozelsky TF, Meyers GE, Sloan JA, et al.  Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol. 2003;21:1669–1674
  70. Pinto A, Fidalgo P, Cravo M, et al.  Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis. Dis Colon Rectum. 1999;42:788–796
  71. al-Sabbagh R, Sinicrope FA, Sellin JH, et al.  Evaluation of short-chain fatty acid enemas (treatment of radiation proctitis). Am J Gastroenterol. 1996;91:1814–1816
  72. Vernia P, Fracasso PL, Casale V, et al.  Topical butyrate for acute radiation proctitis (Randomised, crossover trial). Lancet. 2000;356:1232–1235
  73. Talley N, Chen F, King D, et al.  Short-chain fatty acids in the treatment of radiation proctitis (a randomized, double-blind, placebo-controlled, cross-over trial). Dis Colon Rectum. 1997;40:1046–1050
  74. Mennie AT, Dalley VM, Dinneen LC, et al.  Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet. 1975;2:942–943
  75. Stryker JA, Demers LM, Mortel R. Prophylactic ibuprofen administration during pelvic irradiation. Int J Radiat Oncol Biol Phys. 1979;5:2049–2052
  76. Kilic D, Egehan I, Ozenirler S, et al.  Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol. 2000;57:125–129
  77. Freund U, Scholmerich J, Siems H, et al.  Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy. Strahlenther Onkol. 1987;163:678–680
  78. Baughan CA, Canney PA, Buchanan RB, et al.  A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol. 1993;5:19–24
  79. Martenson JA, Hyland G, Moertel CG, et al.  Olsalazine is contraindicated during pelvic radiation therapy (Results of a double-blind randomized clinical trial). Int J Radiat Oncol Biol Phys. 1996;35:299–303
  80. Resbeut M, Marteau P, Cowen D, et al.  A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol. 1997;44:59–63
  81. Baum CA, Biddle WL, Miner PB. Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. Dig Dis Sci. 1989;34:758–760
  82. Wang J, Zheng H, Sung C-C, et al.  The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys. 1999;45:1289–1296
  83. Wang J, Zheng H, Hauer-Jensen M. Influence of short-term octreotide administration on chronic tissue injury, transforming growth factor b (TGF-b) overexpression, and collagen accumulation in irradiated rat intestine. J Pharmacol Exp Ther. 2001;297:35–42
  84. Weckbecker G, Liu R, Tolcsvai L, et al.  Antiproliferative effects of the somatostatin analogue octreotide (SMS 201–995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992;52:4973–4978
  85. Weckbecker G, Tolcsvai L, Liu R, et al.  Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201–995). Metabolism. 1992;41(suppl 2):99–103
  86. Weckbecker G, Tolcsvai L, Pollak M, et al.  Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res. 1994;54:6334–6337
  87. Patel PC, Barrie R, Hill N, et al.  Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surg. 1994;116:1148–1152
  88. Sartori S, Trevisani L, Nielsen I, et al.  Percutaneous endoscopic gastrostomy placement using the pull-through or push-through techniques (is the second pass of the gastroscope necessary?). Endoscopy. 1996;28:686–688
  89. Sartori S, Trevisani L, Nielsen I, et al.  Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18:463–467
  90. Sartori S, Trevisani L, Nielsen I, et al.  Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. Cancer. 1996;78:1477–1482
  91. Ijiri K, Potten CS. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer. 1983;47:175–185
  92. Ijiri K, Potten CS. Radiation-hypersensitive cells in small intestinal crypts; their relationships to clonogenic cells. Br J Cancer. 1986;7(suppl):20–22
  93. Ijiri K, Potten CS. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer. 1987;55:113–123
  94. Ijiri K, Potten CS. The circadian rhythm for the number and sensitivity of radiation-induced apoptosis in the crypts of mouse small intestine. Int J Radiat Biol. 1990;58:165–175
  95. Pritchard DM, Bower L, Potten CS, et al.  The importance of p53-independent apoptosis in the intestinal toxicity induced by raltitrexed (ZD1694, Tomudex) (genetic differences between BALB/c and DBA/2 mice). Clin Cancer Res. 2000;6:4389–4395
  96. Pritchard DM, Potten CS, Hickman JA. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 1998;58:5453–5465
  97. Bilim V, Kawasaki T, Takahashi K, et al.  Adriamycin induced G2/M cell cycle arrest in transitional cell cancer cells with wt p53 and p21WAF1/CIP1genes. J Exp Clin Cancer Res. 2000;19:483–488
  98. Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells. 1997;15:82–93
  99. Adams JM, Cory S. The Bcl-2 protein family (arbiters of cell survival). Science. 1998;81:1322–1326
  100. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Gene Dev. 1999;13:1899–1911
  101. Bowen JM. The expression of the Bcl-2 family members in the small and large intestine. Adelaide: Department of Medicine, University of Adelaide; 2001;
  102. Bowen JM, Gibson RJ, Keefe DM, et al.  Cytotoxic chemotherapy increases p53 and pro apoptotic Bax and Bak expression in crypts of the rat and human small intestine. Gut (submitted). 2003;
  103. Ikuno N, Soda H, Watanabe M, et al.  Irinotecan (CPT-11) and characteristic changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876–1883

☆ Supported by National Institutes of Health grant nos. CA83719 (M.H.-J.) and CA71382 (M.H.-J.) and the Cancer Council of South Australia (D.M.K.). In addition, support was provided by Amgen (KGF to D.M.K. and R.J.G.) and Pharmacia (Irinotecan to D.M.K. and R.J.G.).

PII: S0749-2081(03)00138-4

doi: 10.1053/j.soncn.2003.10.007

Seminars in Oncology Nursing
Volume 20, Issue 1 , Pages 38-47 , February 2004

Article Tools